Last Updated : Tuesday, December 24, 2019 18:21:17

ALEMBIC PHARMA gets USFDA nod to market opthalmic treatement

VADODARA (BARODA) | AHMEDABAD-GANDHINAGAR | RAJKOT – In a regulatory update as submitted to the Indian Stock Exchanges, Vadodara (Baroda) headquartered Indian Pharma company – Alembic Pharmaceuticals Ltd said of having got USFDA (US Food & Drugs Administration) nod to market ophthalmic treatment – Travoprost Opthalmic Solution USP, 0.004%.

The approved abbreviated new drug application (ANDA) is therapeutically equivalent to the reference listed drug product (RLD), Travatan Ophthalmic Solution, 0.004%, of Alcon Pharmaceuticals Limited (Alcon). Travoprost Ophthalmic Solution USP, 0.004% is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.

Alembic has a cumulative total of 110 ANDA approvals (97 final approvals and 13 tentative approvals) from USFDA.

To read more, please CLICK here.


FacebookGoogle+LinkedinTwitterYouTube, Blogspot, Telegram, Instagram 


Do NOT follow this link or you will be banned from the site!